Stockscreener 앱 받기
3.49
2.65%
0.09
시간 외 거래:
3.71
0.22
+6.30%
Scienture Holdings Inc 주식(SCNX)의 최신 뉴스
Scienture Holdings Sets 1-for-25 Reverse Split Effective October 5, 2026 - Minichart
Scienture Holdings Executes Reverse Stock Split to Retain Listing - TipRanks
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - benzinga.com
Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened - benzinga.com
Scienture Holdings to implement 1-for-25 reverse stock split - Investing.com
Scienture Holdings to implement 1-for-25 reverse stock split By Investing.com - Investing.com South Africa
Scienture Holdings to implement 1-for-25 reverse stock split By Investing.com - Investing.com India
Scienture Holdings, Inc. Announces Reverse Stock Split - The Manila Times
Every 25 shares are expected to become one as Scienture aims to meet Nasdaq's minimum share-price rule. - Stock Titan
Scienture Holdings, Inc. Announces Reverse Stock Split - Moomoo
Total common shares outstanding of Scienture Holdings, Inc. – HAN:4E4 - TradingView
Scienture Holdings, Inc. Statistics – HAN:4E4 - tradingview.com
Scienture Holdings, Inc. (SCNX) Stock Price & News - Syfe
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 - marketscreener.com
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 - Moomoo
Enterprise value to revenue forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Scienture (SCNX) CFO shows no personal stake in company stock - Stock Titan
Scienture Holdings CFO Eric Sherb files initial beneficial ownership statement - Bitget
Scienture Holdings CFO Eric Sherb files initial beneficial ownership statement - Bitget
SCNX | Scienture Holdings, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Scienture (SCNX) Levels: Finishes 4.68% Down at $0.45 on the Day; Trading Range: Price Remains Between $0.43 Support and $0.47 Resistance in the Available RecordWyckoff Upthrust - vinanet.vn
Scienture (SCNX) Quarterly Results: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report: Shares Fall 0.49% in the Latest SessionEarnings Growth Forecast - vinanet.vn
Scienture Q2 Revenue Surges 510% Sequentially on Commercial Product Growth - Minichart
Scienture Q2 Revenue Reaches $343,639 as Net Loss Narrows 58% - Quiver Quantitative
Scienture (SCNX) Q1 2026 Results: Profit Per Share Clears Its Benchmark in the Latest Session; Closing Reaction: Shares Rise 3.76% in Latest TradingOperating Income Trends - vinanet.vn
$Scienture Holdings (SCNX.US)$ LMAO. They give us a buy rating, but wont let us buy. - Moomoo
SCNX Q1 2026 Earnings: Loss Narrower Than Expected, Shares Rise 2.18%Earnings Analysis - vinanet.vn
SCNX Q1 2026 Earnings: Narrower Loss Beats Estimates, but Shares SlipEarnings Analysis - vinanet.vn
Scienture stock jumps 21% on REZENOPY commercial launch - scanx.trade
Scienture Holdings 2Q Loss/Shr 7c >SCNX - moomoo.com
Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses - Quiver Quantitative
SCNX Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView
Scienture Holdings Q2 Results: EPS beats estimate, sales miss - scanx.trade
Three pediatric centers add a liquid blood-pressure medicine for children who struggle to swallow pills - Stock Titan
Scienture Holdings: Q2 Earnings Snapshot - marketscreener.com
Scienture Holdings: Q2 Earnings Snapshot - Barchart.com
Scienture Holdings: Q2 Earnings Snapshot - WKYC
Scienture Holdings (SCNX) grows ARBLI revenue but remains loss-making in Q2 2026 - Stock Titan
Scienture Holdings: Q2 Earnings Snapshot - theheraldreview.com
SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product - Yahoo Finance
Scienture launches naloxone nasal spray for opioid overdose By Investing.com - Investing.com Nigeria
Scienture launches naloxone nasal spray for opioid overdose By Investing.com - Investing.com South Africa
Scienture launches naloxone nasal spray for opioid overdose - Investing.com
Scienture launches naloxone nasal spray for opioid overdose By Investing.com - Investing.com UK
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray - marketscreener.com
Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg - marketscreener.com
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US - Yahoo Finance
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray - Yahoo Finance
Scienture Begins Nationwide Distribution of 10 mg Opioid-Overdose Spray - Stock Titan
10.56%
2.45%
자본화:
|
볼륨(24시간):